Markets

Market

News Details

(11/02/2026 19:30)

AstraZeneca Pharma I Q3 net profit up 5.64% at Rs 32.59 cr

The company reported standalone net profit of Rs 32.59 crore for the quarter ended December 31, 2025 as compared to Rs 30.85 crore in the same period last year, registering a year-on-year growth of 5.64 per cent.

Net revenue of the company rose substantially by 38.90 per cent at Rs 611.57 crore in October-December quarter of this fiscal as against Rs 440.29 crore in the corresponding period last year.

During October-December quarter, operating expenses increased by 56.00 per cent to Rs 566.74 crore from Rs 363.30 crore in year ago period.

Other Income dipped by 35.71 per cent at Rs 5.13 crore versus (Dec'24 Rs 7.98 crore).

Operating Profit slipped by 41.77 per cent to Rs 44.83 crore as against Rs 76.99 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 58.09 per cent in December quarter.

Interest grew by 221.21 per cent y-o-y to Rs 1.06 crore, while Taxation increased by 24.89 per cent at Rs 13.95 crore (Dec'24 Rs 11.17 crore).

Prevent Unauthorized Transactions in your demat account -> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day....................issued in the interest of investors.
KYC is one-time exercise while dealing in securities markets -> Once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.